Regulatory April 22, 2024

Lipidor AB announces new date for publication of Annual Report 2023

Lipidor AB (publ) today announces that the Board of Directors has resolved to postpone the publication of the Annual Report for 2023 to 15 May 2024.

The previously communicated date for publication was 24 April 2024. The reason for the postponement is to synchronise the Annual Report work with the work on the Company's forthcoming rights issue.

For more information, please contact:

Ola Holmlund, CEO
Telephone: +46 (0) 72 50 70 369
Email: ola.holmlund@lipidor.se

The company’s Certified Adviser is Carnegie Investment Bank AB (publ).

About Lipidor AB
Lipidor AB (Nasdaq First North Growth Market: LIPI) (www.lipidor.se) is a pharmaceutical development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The company can develop topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances. Lipidor’s priority project is AKP02G2, which focusses on psoriasis.

Attachments
Lipidor AB announces new date for publication of Annual Report 2023

Lipidor AB announces new date for publication of Annual Report 2023